Effect of the Affordable Medicines Facility—malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data
The table outlines all oral artemisinin monotherapy (oAMT) products found during 2013 ACTwatch surveys. Photos are included where available. Among 6 countries surveyed in 2013, oral AMT was found to be available in the DRC, Cambodia, Myanmar, and Nigeria. No oral AMT was found in Madagascar or Uganda.
This brochure describes how ACTwatch data can be used to monitor markets and provide evidence to guide policy-makers and programme managers.
This presentation was used during the Nigeria National ACTwatch Outlet Survey Dissemination Meeting held on 4th December 2014 in Abuja, Nigeria. The presentation was given by Ms. Chinazo Ujuju, Society for Family Health Nigeria.
ACTwatch antimalarial medicine outlet surveys were conducted in 2013 in the DRC (Kinshasa & Katanga provinces), Cambodia, Madagascar, Nigeria, and Uganda, and in 2014 in Benin, Kenya, Tanzania and Zambia. A representative sample of clusters was selected to provide national estimates (provincial estimates only in the DRC) as well as estimates in urban and rural areas in Benin, DRC, Kenya, Madagascar, Tanzania, Uganda and Zambia. Within selected clusters, a census of all outlets with the potential to sell or distribute antimalarials and/or provide malaria blood testing was completed. All enumerated outlets were administered a series of screening questions to assess eligibility of the ACTwatch outlet survey. Screened outlets were administered additional questions to assess availability of ORS and zinc. This document summarizes the findings from these ORS and zinc availability questions.
This report highlights key trends and most recent findings regarding antimalarial markets across 8 of the ACTwatch sub-Saharan African countries.